Compounds > tesaglitazar
Page last updated: 2024-09-05

tesaglitazar and 3,3',5-triiodothyroacetic acid

tesaglitazar has been researched along with 3,3',5-triiodothyroacetic acid in 1 studies

Compound Research Comparison

Studies
(tesaglitazar)		Trials
(tesaglitazar)		Recent Studies (post-2010)
(tesaglitazar)		Studies
(3,3',5-triiodothyroacetic acid)		Trials
(3,3',5-triiodothyroacetic acid)		Recent Studies (post-2010) (3,3',5-triiodothyroacetic acid)
7413252551147

Protein Interaction Comparison

ProteinTaxonomytesaglitazar (IC50)3,3',5-triiodothyroacetic acid (IC50)
Thyroid hormone receptor alphaHomo sapiens (human)0.0001
Thyroid hormone receptor betaRattus norvegicus (Norway rat)0.0002
Sodium/bile acid cotransporterHomo sapiens (human)6.9

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ferrara, SJ; Scanlan, TS1

Other Studies

1 other study(ies) available for tesaglitazar and 3,3',5-triiodothyroacetic acid

ArticleYear
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
    Journal of medicinal chemistry, 2020, 09-10, Volume: 63, Issue:17

    Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution

2020